Bioactives from Whey: A Sustainable Approach to Enzymatic Production of Sialyl-N-acetyllactosamine

The use of dairy whey to manufacture pharmaceutical products fosters sustainable environmental and economic development. This study represents a new strategy for upgrading of whey to 3'-sialyl-N-acetyllactosamine (3'-SLN) as an important structural component of glycoproteins and a receptor analog capable of forming complexes with hemagglutinins on influenza viruses. N-Acetyllactosamine (LacNAc) was enzymatically produced and purified directly from whey with no pretreatment required. An engineered and recombinantly produced sialidase with trans-sialylation ability from the non-pathogenic Trypanosoma rangeli was then used to transfer sialic acid from whey-derived, sialylated casein glycomacropeptide (CGMP) to this LacNAc. A maximum of 0.92 mM 3'-SLN was obtained at an equimolar ratio of LacNAc to bound sialic acid in CGMP; on the other hand, a molar ratio of 10 gave a fourfold greater 3'-SLN concentration. The variations in the concentration of 3'-SLN and free sialic acid during the hydrolysis reaction were modeled under different reaction conditions using machine learning and mechanistic approaches. The mechanistic analysis of the reaction indicated that the relative initial trans-sialylation rate to hydrolysis rate is directly proportional to the initial LacNAc concentration, with the ratio of trans-sialylation to hydrolysis rate constants equal to 111 M-1. The maximum 3'-SLN yield obtained was 75% based on alpha-2,3-sialic acid bound to CGMP. Separation of CGMP and reuse of enzyme were also investigated in an enzymatic membrane reactor.

Automated summary

The use of dairy whey to produce 3'-sialyl-N-acetyllactosamine (3'-SLN), an important structural component of glycoproteins and a receptor analog for influenza viruses, represents a sustainable approach for environmental and economic development.